multipl
laboratori
develop
test
commerci
avail
assay
emerg
meet
diagnost
need
relat
pandem
date
limit
comparison
data
differ
test
platform
compar
analyt
perform
laboratori
develop
test
ldt
develop
clinic
laboratori
base
cdc
primer
set
four
commerci
avail
fda
emerg
use
author
assay
cepheid
diasorin
holog
panther
roch
coba
total
nasopharyng
swab
ldt
cepheid
xpert
xpress
assay
sensit
assay
agreement
across
specimen
holog
panther
fusion
diasorin
simplexa
roch
coba
fail
detect
posit
specimen
near
limit
detect
cdcbase
ldt
assay
assay
specif
use
cdcbase
ldt
gold
standard
result
provid
initi
test
perform
characterist
rtpcr
highlight
import
multipl
viral
detect
test
platform
avail
public
health
emerg
sinc
first
infect
detect
unit
state
januari
exponenti
growth
case
death
time
write
us
case
count
exce
death
consider
geograph
heterogen
despit
social
distanc
polici
outbreak
diseas
caus
continu
grow
threaten
overwhelm
hospit
system
multipl
state
explos
case
unit
state
highlight
critic
role
diagnost
test
play
medic
public
health
decis
make
contain
mitig
pandem
reliabl
test
result
enabl
appropri
util
scarc
hospit
resourc
includ
person
protect
equip
ppe
neg
pressur
isol
room
well
public
health
resourc
contact
trace
isol
make
rapid
success
march
multipl
assay
becom
avail
includ
fdaeua
test
platform
laboratori
develop
test
ldt
use
highcomplex
clinic
laboratori
solv
suppli
chain
difficulti
clinic
laboratori
implement
multipl
assay
use
scarc
reagent
resourc
render
thorough
comparison
challeng
clear
understand
analyt
paramet
option
import
help
guid
assay
select
clinic
laboratori
suppli
chain
consider
subsid
final
specimen
use
compar
assay
uw
panther
fusion
diasorin
simplexa
assay
samesampl
comparison
perform
specimen
store
c
less
hour
freezethaw
inconclus
result
one
two
target
detect
consid
posit
due
high
specif
assay
limit
crossreact
seen
primer
set
work
approv
consent
waiver
univers
washington
institut
review
board
ccbi
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
panther
fusion
ruo
eua
assay
slightli
less
sensit
cdcbase
ldt
miss
one
positiveinconclus
sampl
set
tabl
one
addit
specimen
initi
neg
ruo
reagent
detect
upon
repeat
panther
fusion
eua
assay
discord
specimen
either
inconclus
one
target
two
detect
high
averag
ct
cdc
ldt
test
neg
specimen
gener
detect
result
holog
panther
fusion
assay
diasorin
simplexa
next
compar
diasorin
simplexa
assay
cdcbase
ldt
specimen
posit
neg
demonstr
complet
concord
two
platform
tabl
simplexa
gener
one
addit
posit
specimen
neg
holog
panther
fusion
tabl
discord
specimen
detect
cdcbase
ldt
ct
confirm
diasorin
simplexa
result
roch
coba
next
compar
roch
coba
assay
cdc
ldt
neg
demonstr
complet
concord
two
platform
tabl
one
posit
detect
roch
assay
specimen
ct
ldt
across
posit
specimen
ct
slightli
higher
ccbi
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
perform
pairwis
comparison
next
compar
twentysix
specimen
posit
neg
anoth
highcomplex
hospit
laboratori
labcorp
seattl
also
test
cepheid
xpert
xpress
assay
tabl
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
evalu
demonstr
high
sensit
egen
primer
set
use
cepheid
assay
panther
fusion
somewhat
less
sensit
either
ldt
diasorin
howev
panther
fusion
detect
rna
one
specimen
inconclus
target
detect
thu
presum
posit
uw
cdc
ldt
roch
assay
perform
coba
platform
detect
posit
sampl
discord
specimen
low
viral
titer
uw
cdc
ldt
c
one
inconclus
specimen
therefor
conclud
test
assay
show
good
sensit
detect
uw
cdc
ldt
cepheid
xpert
xpress
assay
best
similar
sensit
follow
roch
coba
diasorin
simplexa
panther
fusion
assay
result
chiefli
limit
small
sampl
set
use
compar
differ
assay
well
asynchron
comparison
allow
pairwis
comparison
earli
pandem
instanc
asynchron
panel
greatli
affect
cdc
ldt
versu
holog
panther
fusion
comparison
greater
proport
high
ct
posit
specimen
result
lower
measur
sensit
panther
fusion
clinic
practic
minor
differ
sensit
like
littl
effect
holog
panther
fusion
assay
perform
vtm
specimen
given
ct
rang
observ
clinic
popul
despit
limit
data
provid
basi
differ
analyt
sensit
differ
ct
may
seen
platform
instanc
recent
report
demonstr
slightli
higher
analyt
sensit
cepheid
xpert
xpress
assay
compar
roch
coba
test
slightli
lower
sensit
ccbi
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
diasorin
simplexa
assay
compar
modifi
cdc
assay
concord
data
also
note
analyt
sensit
critic
import
mani
consider
factor
assay
platform
select
includ
assay
avail
cost
turnaround
time
throughput
result
provid
earli
assess
perform
characterist
five
separ
assay
detect
march
reagent
avail
rtpcr
assay
heavili
constrain
necessit
limit
assay
comparison
platform
examin
accept
perform
criteria
test
earli
part
pandem
suppli
chain
rtpcr
attempt
catch
test
demand
look
forward
addit
assay
comparison
data
ccbi
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
ccbi
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
tabl
tabl
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
authorfund
grant
medrxiv
licens
display
preprint
perpetu
certifi
peer
review
copyright
holder
preprint
version
post
april
http
ccbi
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
certifi
peer
review
copyright
holder
preprint
version
post
april
